ABSTRACT: The aims of current asthma treatment are to suppress airway inflammation and control symptoms, and corticosteroids maintain a commanding position in this role.
Airway inflammation and remodelling
The chronic airway inflammation of asthma is characterized by infiltration of the airway wall and lumen by diverse effector cells, including T-lymphocytes, eosinophils, monocytes/macrophages, mast cells, and occasionally, neutrophils [1±3] . The mobilization, activation and trafficking of these effector cells to the airway are controlled by a complex cytokine milieu derived from activated CD4+ T-helper (Th) cells and also from other resident airway cells including airway smooth muscle and epithelial cells. T-helper cells of type 2 variety (Th2) secrete a Th2 profile of cytokines, after cognate stimulation of the naive T-cell by antigen presenting cells, such as the dendritic cell and the alveolar macrophage ( fig. 1 ). The Th2 cytokines include interleukins (IL)-4, -5, -9, -10 and -13. These cytokines promote various elements of allergic inflammation (table 1) , including propagation of the Th2 phenotype, isotype-switching from immunoglobulin (Ig)-G1 to IgE synthesis, eosinophil mobilization, maturation and activation and mast cell activation [4] . Additionally, the airway wall undergoes chronic structural changes labelled as remodelling, which include thickening of the airway smooth muscle due to hypertrophy and hyperplasia, myofibroblast activation with increase in subepithelial basement membrane collagen deposition, angiogenesis and increase in submucosal blood vessels and an increase in goblet cell numbers in the airway epithelium [5±8] . These changes are also variably influenced by Th2 cytokines, and certain growth factors [9, 10] .
The exact link between the chronic inflammatory and remodelling processes and the clinical presentation of asthma is unclear in terms of the pathophysiological mechanisms and of the contribution of the components of these processes to bronchial hyperresponsiveness, airway narrowing and the acute exacerbations that characterize the disease. The overwhelming hypothesis is that these are intricately related such that inhibition or prevention of the inflammatory process should improve the control of asthma, an idea supported by the potent actions of topical corticosteroids in controlling the eosinophilic and lymphocytic inflammation of asthma, while being most effective in restoring lung function and bronchial hyperresponsiveness [9, 10] . However, identification of the key immunological and inflammatory processes that lead to functional abnormalities and symptoms remain to be elucidated.
Limitations of current therapy
Despite the introduction of new agents such as the leukotriene inhibitors, corticosteroids remain the antiinflammatory drug of choice for the majority in the treatment of chronic asthma [11, 12] . However, treatment failure and drug-related side-effects pose serious limitations to their use [13] . Severe and difficult-to-treat asthmatics are characterized by ongoing symptoms and frequent exacerbations despite the use of existing antiinflammatory and bronchodilator therapies. These patients are frequently prescribed corticosteroids to which their disease is partially responsive and they endure the adverse consequences of high dose inhaled and systemic corticosteroid therapy [13, 14] . Amongst severe asthmatics, up to 25% demonstrate relative unresponsiveness to the therapeutic but not to the adverse effects of corticosteroids [15, 16] . The identification of novel therapeutic targets and subsequent development of specific and safe therapeutic agents therefore, represents a major challenge in asthma therapy. In addition to attempting to reverse established changes in the airways resulting from chronic inflammation and airway remodelling, the prevention of allergy and asthma remains an important consideration given the rising prevalence of these conditions in many industrialized countries [17] .
Immunological imbalance: T-helper cell balance
The vast majority of asthmatics have an atopic background, in whom the inflammatory process of asthma is assumed to be driven following sensitization and reexposure, or challenge by common aeroallergens. However, the inflammatory abnormalities in nonatopic asthma also bear many similarities to those observed in the allergic inflammatory process, including the presence of eosinophils, activated CD4+ T-cells, and the expression of Th2-derived cytokines [18] . These findings suggest that most asthmatics may benefit from an approach that targets mechanisms of allergic sensitization and inflammation.
Allergens are taken up by specialized cells within the mucosa such as dendritic cells (antigen-presenting cells), and subsequently processed, following which peptide fragments are presented to naive T-cells. The activation of naive T-cells requires direct signalling by two distinct pathways ( fig. 1 ): firstly via the CD4+ T-cell receptor through the antigen-presenting cell (APC)-bound antigen to major histocompatability (MHC)-II complex and, secondly, via the costimulatory pathway linked by the B7 family and the T-cell bound CD28 [19] . T-cells stimulated via the T-cell receptor (TCR) in the absence of costimulatory signalling are incapable of IL-2 secretion and subsequent activation and therefore, enter an anergic state [20] . CD28 itself has two major ligands, B7.1, which inhibits Th2 cell activation and development, and B7.2, which induces T-cell activation, and Th2 development. An important third ligand, cytotoxic T-lymphocyte associated protein-4 (CTLA4), is expressed on activated T-cells, binds CD28 with enhanced avidity and acts as a negative regulator of T-cell function by inhibiting Th2 differentiation [21, 22] . In those who later develop an allergic response, naive T-cells differentiate into the Th2 subtype.
T-cell profiles in the newborn demonstrate a Th2 bias suggesting that prenatal influences are involved in T-cell priming [23] . Th1 cells form a natural counterbalance to Th2 cells driving protective cell-mediated immunity (CMI), and are induced on exposure to foreign agents including protozoa and bacteria. Th1 responses are characterized by the induction of CMI responses and the synthesis of IgG2a, while Th2 responses are of the humoral-type, inciting the production of IgE and IgG4. The identification of ways to prevent, control or even reverse the process of Th2 immunodeviation has become a focus for the development of new strategies to control asthma and allergies.
Prevention of T-cell activation
Three main thrusts of research into new therapies have developed: 1) preventing T-cell activation; 2) prevention or reversal of Th2 polarization, and; 3) ablation of the effects of Th2 cytokines and downstream mediators (table 2) . Many of the potential ways of achieving these objectives have been investigated in animal (mainly murine) models, and therefore, their applicability to human asthma and allergic diseases remains unclear given the inherent variability within varied species.
T-cell immunomodulators
Cyclosporin A and the functionally-related, tacrolimus (FK506), are powerful immunosuppressant agents used widely to prevent immune rejection in organ transplantation. These compounds inhibit T-cell growth by creating a block in the G 0 phase of development through inhibition of T-cell growth factors including IL- T-cell depletion: anti-CD4 monoclonal antibody CD4+ T-cells appear central to the orchestration of allergen-mediated airway disease. Depletion of T-cells in murine sensitized and allergen-challenge models using recombinant monoclonal antibodies results in a complete ablation of airway hyperresponsiveness and airway eosinophilia [52] . Conversely, antibody-mediated CD8+ T-cell depletion augments BHR and eosinophilic inflammation in the allergen-challenge model [53] . A preliminary clinical trial in asthma has evaluated the use of a single dose of anti-CD4 monoclonal antibody in severe corticosteroid dependent asthma [54] . This treatment led to a reduction in circulating CD4+ T-cell numbers and caused an improvement in morning and evening peak expiratory flows but did not significantly impact on asthma symptoms. Early studies have also suggested some benefit of this approach in the CD4+ dependent processes of multiple sclerosis [55, 56] and collagenarthritis [57] .
It is likely that other T-cell subsets may also be important in asthma. Recent investigations have highlighted the existence of CD8+ T-cells (i.e. TC2), which secrete Th2 type cytokines and their influence on the mediation of allergic airways disease is as yet to be established [58±60] . Further uncertainty regarding the approach of CD4 depletion relates to the induction of CD4 lymphopenia and immunosuppression and the resultant risk of opportunistic infection and neoplasia [61±63] . Nondepleting CD4 antibodies have been generated but are as yet untried in pulmonary disease [64] .
Inhibition of T-cell costimulation: cytotoxic T-lymphocyte associated protein-4-immunoglobulin
Although corticosteroids inhibit antigen uptake and processing, they do not appear to impact on antigen presentation [65] . Therefore, the potential for disruption of antigen presentation by specific inhibition of costimulatory molecule interaction has been recognized and studied in murine models. A recombinant fusion protein consisting of the extracellular domain of CTLA4 linked to the constant region of IgG1, known as CTLA-4-Ig, binds B7 molecules with an affinity similar to that of membrane CTLA4. It therefore, acts as a powerful inhibitor of B7: CD28 mediated costimulation. T-cell activation following B7:CD28 signalling may be blocked using the soluble protein ligand CTLA4-Ig, and this can substantially reduce BHR, bronchoalveolar lavage (BAL) eosinophilia and specific IgE responses when given either prior to sensitization or to allergen challenge [66] . CTLA4-Ig reduced IL-4 and IgE levels while IFN-c and IgG2a were unchanged, suggesting downregulation of Th2 response without upregulation of the Th1 response [67] . Similar outcomes are observed following monoclonal anti-B7.2 (anti-CD86) treatment in allergen-challenged mice [68] . Thus, CTLA4-Ig is potentially a powerful immunomodulator with the potential of suppressing Th2 based responses to allergens in humans.
Modulation of T-helper 1/T-helper 2 differentiation
Specific attempts to alter Th1/Th2 balance by enhancing Th1 and abrogation of Th2 responses have been the major thrust of immune approaches to the prevention and treatment of allergies and asthma. Induction of Th1 responses may have a direct suppressive effect on Th2 mediated inflammatory processes (table 3) . The most direct approaches include administration of cytokines that will induce activation of Th1 pathways (e.g. IFN-c, IL-12 and IL-18) or of blocking antibodies that inhibit the effect of Th2-related cytokines (e.g. anti-IL-4, anti-IL-5, anti-IL-9, and anti-IL-13). Blood Airway
IFN: interferon; IL: interleukin; BHR: bronchial hyperresponsiveness; IgE: immunoglobulin-E; TNF-a: tumour necrosis factor-alpha.
Inhibition of allergy and asthma by T-helper 1 related cytokines
Interferon gamma IFN-c, released from CD4+(Th1) and CD8+(TC2) cells, is a critical factor controlling the balance of Th1/Th2 development, and exerts an inhibitory effect on Th2 cells [4] . IFN-c is also a powerful and relatively specific inhibitor of IL-4-induced IgE and IgG4 synthesis by Bcells. A reduced production of IFN-c by the T-cells of asthmatic patients is seen and correlates with disease severity [69] . Intra-tracheal IFN-c in allergen-sensitized and -challenged mice causes a dose-dependent reduction in BAL IL-5 levels and airway T-cells and eosinophils [70, 71] . Intraperitoneal IFN-c also reduced lung Th2 cytokine levels, attenuated allergen-induced BHR with concomitant reduction in BAL eosinophilia, while an IFN-c-blocking antibody led to an increase in airway CD4+ T-cells and BHR [72] . The inhibition of eosinophil recruitment appears to be dependent on the inhibition of CD4+, but not on CD8+ T-cell accumulation within the airways [70, 73] . Inhalation of IFN-c by nonasthmatic humans increases epithelial lining and BAL fluid IFN-c levels but does not affect serum IFN-c levels and therefore, may avoid toxicity associated with systemic administration [74, 75] . However, in one study of subcutaneous IFN-c therapy in steroid-dependent asthma no effect on lung function or treatment requirement was observed despite a significant reduction in circulating eosinophil numbers [76] . . IL-18 and IL-12 have synergistic effects on Th1 development, which may be due to reciprocal upregulation of their receptors. IL-18 may be important in the control of allergen-induced BHR by vaccination. Vaccination using heat-killed Listeria monocytogenes caused a marked inhibition of allergeninduced BHR and airway inflammation, associated with conversion to the Th1 phenotype in mice [92, 93] . This effect was IL-12-dependent and associated with a marked upregulation of IL-18 messenger ribonucleic acid (mRNA) expression. These studies also demonstrated that administration of an adjuvant after allergen exposure, was able to reverse established BHR. The direct administration of IL-18 in the murine asthma model provides more confusing results; although IL-18 appears to play a protective role when administered with allergen challenge, administration with sensitization paradoxically increased IgE and IL-5 levels and promoted BAL eosinophilia [94, 95] . Thus, IL-18 appears to be involved in vaccination-mediated inhibition of Th2 responses and may have properties directly driving BHR in mice.
Inhibition of T-helper 2 related cytokines

Interleukin-4
IL-4 has a central role in Th cell development as a potent inducer of Th2 maturation from the naive T-lymphocyte [96, 97] . Additionally, IL-4 induces the isotype-switch necessary for IgE synthesis [98] , upregulates IgE receptors [99, 100] and vascular cell adhesion molecule-1 (VCAM-1) expression on vascular endothelium, thus facilitating endothelial passage and accumulation of eosinophils [101] . IL-4 is therefore, an attractive target to inhibit, resulting in downregulation of Th2 activation. Anti-IL-4 monoclonal antibody treatment of mice prior to allergic sensitization markedly reduces IgE synthesis [102] , but does not appear to inhibit airway eosinophilia or BHR [103] . A recombinant soluble IL-4 receptor (sIL-4R) has been designed as a mimic of the cell-surface receptor, which thus binds and sequestrates free IL-4, but because these soluble receptors lack transmembrane and cytoplasmic domains, they act as an IL-4 receptor blocker. In murine studies, sIL-4R reduces allergenspecific IgE responses, airway hyperresponsiveness, VCAM-1 expression and eosinophil accumulation [104] . Preliminary human asthma studies with single doses of sIL-4R have shown acceptable tolerance, improvement in lung function and a reduction in rescue b 2 -agonist requirement [105] . Additionally, a trend towards a reduction in serum eosinophilic cationic protein (ECP) and exhaled nitric oxide (NO) levels suggests suppression of inflammation by this agent. A recombinant mutant human protein (BAY 16-9996) binds the IL-4 receptor a-but not cc-chain, and therefore, antagonises receptor transduction. This protein substantially reversed allergen-induced BHR with a reduction in airway inflammation in a primate model [106] .
Another approach to inhibition of IL-4 production is to target the control of transcription factors of the IL-4 gene. Signal transduction and activation of transcription-6 (STAT-6) responsive elements are found in the promoter region of IL-4 inducible genes and this transcription factor is expressed at abnormally high levels in the epithelium of severe asthmatics [107] . STAT-6 knockout mice demonstrate a defect in IL-4 and IL-13 mediated signal transduction [108] . The potential utility of STAT-6 targeted therapies is highlighted by the ability of STAT-6 directed antisense oligonucleotides to markedly downregulate germline Ce mRNA levels, reflecting inhibition of IL-4-dependent IgE isotype switching [109, 110] .
Interleukin 5
Eosinophil mobilization and trafficking, their maturation and maintenance are largely promoted by the Th2 cytokine, IL-5, making it an attractive therapeutic target in eosinophilic conditions such as asthma and rhinitis. Ablation of the effects of IL-5 has been accomplished with antisense oligonucleotides in rodent models where a reduction in IL-5 protein levels is followed by a reduction in allergen-induced eosinophilia and BHR [111] . Importantly, this suppression of lung eosinophilia was maintained for 17 days following a single intravenous treatment.
Monoclonal antibodies used to block IL-5 in mouse, guinea-pig, rabbit and monkey studies provided a sustained reduction in antigen-induced airway eosinophilia but had little effect on antigen-induced BHR [112±114]. Two humanized forms of anti-IL-5 (SB-240563 and Sch 55700) are now available with the potential for clinical studies [115, 116] . In mild asthmatics, SB-240563 had a marked inhibitory effect on both airway and peripheral blood eosinophil levels and on allergen-induced sputum eosinophilia following single subcutaneous administration [117] . However, as with the studies in mouse, rabbit and monkey, no significant effect on bronchial responsiveness or the late phase response to allergen-challenge was observed. Phase-I trials in severe persistent asthma have provided similar results [118] . IL-5 blocking antibodies prevent the mobilization and subsequent trafficking of eosinophils to the lung in allergic asthma, but are unable to influence BHR or the late phase response. Currently, studies are in progress to determine whether anti-IL-5 blocking antibodies can improve the control of asthma, despite their apparent lack of protection against BHR.
Recent studies on IL-5 signalling ( fig. 3 ) suggest that various IL-5-dependent functions are mediated by distinct and separate secondary messenger systems [118] . Thus, targetting such pathways may lead to inhibition of IL-5 effector functions. The anti-apoptotic effects of IL-5 on eosinophils are dependent on the activation of lyn-, Janus kinase-2 (Jak2) and Raf-1 kinase, of these, only Raf-1 is necessary for eosinophil activation and degranulation [119, 120] . Lyn-kinase dependent signalling may be specifically inhibited by a peptide inhibitor, resulting in inhibition of lyn-dependent IL-5 signalling without affecting Jak2 dependent IL-5 signalling. This inhibitor blocks allergen-driven airway eosinophilia [121] . The transcription factor GATA-3 is critical for IL-5 expression in Th2 cells, and increased GATA-3 gene expression in association with IL-5 mRNA positivity has been shown in airway cells isolated from patients with asthma. These findings support a causal association between augmented GATA-3 expression and dysregulated IL-5 expression and asthma [122, 123] . Specific inhibition of GATA-3 expression using dominant negative GATA-3 transgenic mice led to a reduction in Th2 cytokine expression and marked attenuation of airway eosinophilia, mucus production, and IgE synthesis [124] . These outcomes could also potentially be achieved using antisense oligonucleotide technology.
Interleukin-9
IL-9 has been identified in airway tissue in asthma and is known to induce BHR, elevated serum IgE, mucin gene transcription and epithelial CC chemokine release [125± 128], and thus is a broadly attractive therapeutic target in asthma [129] . One mechanism by which IL-9 may induce airway eosinophilia is by enhancing IL-5 receptor expression, thereby increasing the differentiation and survival of eosinophils [130] . activity has been accomplished in the mouse by intratracheal instillation of monoclonal anti-IL-9 antibody [131] . Anti-IL-9 significantly inhibited BHR, airway eosinophilia, serum IgE, airway inflammatory cell infiltration and mucin production induced by allergen, demonstrating a surprisingly broad inflammatory effect for this cytokine. As yet there are no reported clinical trials adopting IL-9 as a therapeutic target.
Interleukin-13
This cytokine shares 70% of its sequence homology with IL-4 and despite a degree of functional redundancy due to sharing of the IL-4Ra subunit, a specific role in the development of asthma has been demonstrated in murine models [132±134] . Notably IL-13 does not share the IL-4 influence on specific induction of the Th2 phenotype from naive Th0 cells. By using a soluble form of the IL13Ra chain of the IL-13 receptor, known to bind IL-13 exclusively, these groups demonstrated a significant reduction in airway hyperreactivity, airway eosinophilia and mucus hyperplasia. Curiously, when administered after the initial allergen sensitization however, this agent had no effect on serum IgE levels [133, 134] . Notably, an IL-13 blocking antibody reduced BHR independently of IL-5 [135] .
T-helper 1/T-helper 2 modulation by vaccination
An indirect way of modulating Th1/Th2 balance has been to boost innate immunity by the use of vaccines, particularly for redirection of the Th2 response in favour of the Th1 response. Several approaches are currently under investigation, and these may even raise the possibility of preventing the development of asthma and allergic diseases. The beneficial effects of specific immunotherapy may result from increasing Th1 immune responses while the development of peptide immunotherapy may lead to a more effective and safer treatment.
Mycobacterium species
The potential benefit of Bacille Calmette-Guerin (BCG) vaccination in atopic diseases was first raised by a study in Japanese school children, in whom an association between BCG vaccination and a diminished incidence of atopy and allergic disease was observed, suggesting a role for early mycobacterial exposure in the subsequent development of atopic responsiveness [34] . Experimental models have supported this concept using the nonpathogenic mycobacterial products of Mycobacterium bovis and Mycobacterium vaccae. Mice vaccinated with BCG prior to allergen sensitization had increased IFN-c and decreased IL-4 and IL-5 expression along with reduced levels of airway T-cells and eosinophilia and bronchial reactivity [136, 137] . Mycobacterium vaccae is ubiquitously present in the soil as a saprophyte and can evoke a strong production of IFN-c. A suppression of Th2 activation has been demonstrated using heat-killed M. vaccae in mice [138±140], and these studies have opened the way to clinical studies in human asthma [138] .
Deoxyribonucleic acid vaccines: cytosine-guanosine repeat motifs
The cytosine-guanosine dinucleotide repeat, when present in a particular base context, is known as a CpG motif and has been recognized as an important procaryotic immunomodulatory effector whose role is probably that of a warning or priming agent against bacterial infection [141] . This motif is expressed at a very low frequency in vertebrates, in a nonfunctional methylated form, and is without function. Rodent studies highlight a potential function of synthetic CpG motifs in vertebrates, where a potent effect on lymphocyte function has been found [142] . CpG vaccination directly induces antigen-presenting cells and B-lymphocytes to release IL-12, IL-18 and tumour necrosis factor-alpha (TNF-a), effectively suppressing Th2 responses by inducing the Th1 phenotype. These CpG oligodinucleotides (ODN) are effective in preventing the development of eosinophilic airway inflammation, allergen-induced elevation of serum IgE and BHR in murine asthma models [142] . These ODN not only effectively prevent Th2 type responses by pre-administration and co-administration with allergen-challenge but also reduce established inflammation [142±144] . Further, these motifs show a large degree of flexibility towards the dose and the route of administration, being active following transmucosal [145] , inhaled and parenteral administration [142] . As an added potential, a deoxyribonucleic acid (DNA) vaccine containing this motif may provide a more effective adjuvant than the widely used, alum. The clinical efficacy and safety of such CpG motifs needs evaluation [146] and such trials are currently being considered.
Potential drawbacks of manipulating T-helper 1/T-helper 2 balance
The mounting evidence for Th2 cell activation in allergic asthma suggests downregulation or ablation of the Th2 response to be an appropriate aim in treating asthma and allergic disorders. However, the consequences of such a strategy are as yet unclear. Two potential outcomes need consideration; first the consequences of Th2 ablation and second, those of allowing a Th1 dominated immune activation. Parasite exposure is known to induce Th2 type cytokine synthesis [147±149], and mice with Th2 cytokine deletions demonstrate impaired parasite clearance [150±152] . Although early Th1 expression may be a more important response to acute phase parasitaemia, subsequent parasite clearance appears to be more Th2 cytokine dependent [152, 153] . Autoimmune diseases including experimental allergic encephalomyelitis, myasthenia gravis and hypothyroidism may be derived from an exuberance of Th1 activity [154±156], raising the concern that increased Th1 cell activity may induce these autoimmune diseases. Several reports note associations between IFN-c, IFN-b and IL-12 exposure and the development or exacerbation of autoimmune processes [154, 157±159] . Th1 cells may contribute to asthmatic inflammation. In adoptive transfer studies of Th1 cells in mice, a prolonged enhancement of cell-mediated immune responses was observed [160] , and passive transfer of Th1 cells with Th2 cells induces enhanced tissue eosinophilia compared to when Th2 cells alone were administered [161±163]. However, in other studies in mice and rats, transfer of allergen-specific Th1 cells [164] inhibited the effects of allergen-specific Th2 cells, namely BAL eosinophilia and BHR in rats, without itself inducing any inflammation [165] . Allergen-specific Tc1 cells also diminished allergen-induced BHR and BAL eosinophilia [163] . Nevertheless, IFN-c produced by Th1 cells may activate epithelial cells to induce the production of pro-inflammatory cytokines and chemokines [ 166± 168] .
Two further observations appear important to the contribution of Th1 type processes to asthma. First, the prominent expression of the Th1 dependent transcription factor, STAT1, in stable asthma [169] and second, the association between respiratory viral infections and asthma [170, 171] . Viral infections induce Th1 expression with upregulation of TNF-a and VCAM1 expression supporting a role for Th1 mediated processes in asthma exacerbation [169, 172] . Therefore, caution is necessary in studies that aim towards altering the balance of the Th1/Th2 in the treatment of asthma and allergic diseases.
Specific immunotherapy
Specific immunotherapy (SIT) is a treatment aimed at the induction of specific unresponsiveness, or anergy, in peripheral T-cells to peptide epitopes. Peripheral T-cells following SIT are characterized by reduced cytokine production and attenuated proliferative responses to specific allergens [173] . This process is initiated by an autocrine effect of IL-10 produced by antigen-specific Tcells [174±176]. IL-10 induces anergy by inhibition of CD28-costimulatory molecule signalling [177, 178] and also by anti-inflammatory effects on basophils, mast cells and eosinophils [4] . There are reduced levels of IL-4 and IL-5 and increased IFN-c production, indicating a shift of the T-cells towards an increased Th1 response at the expense of Th2 responses [179, 180] . This treatment has been successfully used in asthma and allergic rhinitis and for venom allergy [181, 182] , but is usually most useful in subjects allergic to single allergens such as grass pollens, and in subjects with mild forms of allergic diseases [183, 184] . Recently, cloning of epitopes of allergens has provided a higher level of epitope purity than previously available, and there has been a greater understanding of the specific mechanisms of tolerance induction. These factors may lead to a wider application of SIT in atopic disease, using better characterized peptides which are more effective but with a lesser risk of side-effects, in particular anaphylaxis.
Peptide immunotherapy
Peptide immunotherapy can be considered as a refinement of SIT, with the specific intent of inhibition of T-cell activation independent of IgE-mediated inflammatory processes. Synthetic MHC-restricted oligopeptides mimicking recognized epitopes of the major cat allergen dI (Fel dI), modified by single amino acid substitution have been produced and are noted to have variable effects on T-cell proliferation and cytokine production by Fel dI specific T-lymphocytes. Such constructs have been demonstrated to induce IgE-independent late-phase bronchoconstrictor responses in cat-sensitive mild asthmatics [185] . Ex vivo studies subsequently demonstrated a dose-dependent reduction in T-cell IL-4 production following cat peptide, not observed following whole cat hair extract [186] . In vitro cat-peptide studies also showed a reduction in IL-2, IL-4, IL-5 and IFN-c release from peripheral blood T-cells and a reduction in CD40 ligand (CD40L) expression, resulting in a diminished ability of these cells to give help to B-cells for the production of IgE [187, 188] . In a six-week trial of cat peptide immunotherapy in asthma, a reduction in IL-4 levels was again observed and was accompanied by an improvement in the provocative dose causing a 20% fall in (PD20) forced expiratory volume in one second (FEV1) [187] , although there was no effect on IFN-c or IgE, suggesting the possible induction of a Th2 to Th0 change. The possibility of selective induction of clonal anergy is invited by this approach and phase I and II studies of cat peptide immunotherapy are currently being launched.
Anti-immunoglobulin-E antibody
Studies of the recombinant human anti-IgE antibody (rhu MAb-E25, Xolair) are now in phase IV in asthma and allergic rhinitis. E25 binds to free IgE at the high affinity receptor-binding site (FceR 1 ), preventing the crosslinking of IgE bound to effector mast cells and basophils. This strategy ensures that the antibody is nonanaphylactogenic. The antibody may be delivered by subcutaneous injection on a 2±4 weekly schedule, dosing based on weight and serum IgE levels. Tolerance and adverse effect profiles are thus far acceptable with no reports of serum sickness, hypersensitivity reaction or the development of anti-E25 antibodies. E25 induces a dose-dependent reduction in serum free IgE associated with a reduction in basophil FceR 1 expression and histamine release [189, 190] . A significant improvement in both early [191] and late phase [192] bronchoconstrictor responses to allergenchallenge and a reduction in methacholine-induced hyperresponsiveness, with a reduction in sputum eosinophil numbers have been reported following E25 administration. Results of several clinical trials show subjective improvement and significant effects on corticosteroid reduction in moderate to severe asthma [193] , and allergic rhinitis [194] . This treatment should become available in the near future, and its initial role may be in severe atopic asthma, although it is not known whether E25 is also effective in nonatopic asthma.
Inhibition of eosinophil activation and chemoattraction
IL-5 is involved in the maturation and mobilization of eosinophils and cooperates with chemoattractant cytokines (chemokines) in chemoattraction and tissue activation of eosinophils.
Chemokine receptor antagonists
Chemokines are inducible pro-inflammatory proteins whose key function is leukocyte chemoattraction and activation. Three families are currently described, distinguished on a structural basis into C, CC and CXC families [195] . Chemokine effects are mediated by chemokine receptors and differential cell receptor profiles allow cellspecific attraction [196±198] . Thus, the CC chemokine eotaxin has an eosinophil selective role in eosinophil recruitment due to selective expression of the eotaxin receptor CCR3 on the eosinophil [199, 200] . Chemokines are however, also involved in the recruitment of monocytes, dendritic cells, T-lymphocytes, NK cells, Blymphocytes and basophils.
Antagonism of chemokine receptor signalling has been accomplished by modification of endogenous agents to create high-affinity receptor antagonists. These agents, which include met-regulated upon activation normal T-cell expressed and secreted (RANTES) and met-Ckb7 [201± 203] , are potent CCR3 specific antagonists which inhibit CCR3 receptor signalling and consequent eosinophil migration. To date several small-molecular weight CCR3 antagonists have been developed and await clinical evaluation. One potential strategy combines the inhibition of both IL-5 and eotaxin, a double-pronged approach that would reduce both mobilization, chemoattraction and activation of eosinophils more effectively given the cooperation between IL-5 and eotaxin demonstrated in in vivo models [204, 205] . Such a combined approach may lead to clinical improvement.
Blocking adhesion molecules and integrins
Eosinophil migration to sites of allergic inflammation is specifically mediated by interactions between endothelium, epithelium and eosinophil adhesion molecules including the a 4 -integrin very late antigen-4 (VLA-4) [206] . a 4 -Integrins are also implicated in human lymphocyte coactivation [204] . An a 4 -integrin monoclonal antibody inhibited inflammation and BHR in a sensitized mouse model [207] , and also eosinophilic inflammation and BHR induced by eotaxin in IL-5 transgenic mice [204] . Peptido-mimetic small molecule VLA-4 inhibitors, administered prior to allergen challenge, also prevent increases in VLA-4 + leukocytes (eosinophils, lymphocytes and macrophages) in lung tissue while significantly inhibiting early and late phase allergic responses [208] . Similar approaches inhibiting interactions between leukocyte function associated antigen-1 (LFA-1) and intercellular adhesion molecule-1 (ICAM-1) have also proven effective in blocking eosinophil adhesion and transmigration [209] .
Inhibition of pro-inflammatory cytokines and pathways
Several pro-inflammatory cytokines such as TNF-a [210] and IL-1b [211] have been shown to be overexpressed in asthma, and exposure to environmental endotoxin such as that present in house dust [212] may lead to further activation of a panel of such proinflammatory cytokines. Activation of the transcription factor, NFkB, which can regulate the production of a range of pro-inflammatory cytokines including IL-1, IL-6, IL-8 and TNF-a but also adhesion molecules ICAM-1 and VCAM-1, has been shown in the airway epithelium and macrophages of patients with mild asthma [213] . Similarly, increased expression of the transcription factor, AP-1, has also been reported [214] .
Tumour necrosis factor-a TNF-a increases airway responsiveness in BrownNorway rats [215] and in humans, together with an increase in sputum neutrophils [216] . TNF-a also potently stimulates airway epithelial cells to produce cytokines including regulated upon activation, normal Tcell expressed and secreted (RANTES), IL-8 and GM-CSF, and increases the expression of the adhesion molecule, ICAM-1. TNF-a has a further synergistic effect with IL-4 and IFN-c to increase VCAM-1 expression on endothelial cells [217, 218] . These factors indicate that TNF-a may be an important mediator in initiating chronic inflammation in the airways. Several approaches to inhibition of TNF-a synthesis and effects are now under investigation in asthma, including monoclonal antibodies to TNF-a and soluble TNF-a receptors. An anti-TNF-a antibody has retarded the progression of severe rheumatoid arthritis with significant clinical amelioration [219] , but has not been tried in asthma. This antibody may have therapeutic effects in severe asthma. Inhibitors of TNF-a converting enzyme (TACE), or of the cysteine protease caspase-1 (IL-1 converting enzyme, ICE) are also potential anti-inflammatory compounds that may be used in asthma, and are currently under development. Recent attention has also been focused on intracellular signalling cascades such as inhibitors of p38 MAP kinase which inhibit the synthesis of pro-inflammatory cytokines in vivo [220, 221] . In this mouse model, inhibition of p38 kinase activity markedly reduced cytokine-associated inflammation and inhibited lipopolysaccharid (LPS)-induced TNF-a production while allergen-induced airway eosinophilia was all but abolished.
Interleukin-1
IL-1 co-induces CD4+ T-cell proliferation and IL-2 secretion following interaction of T-cells with antigen presenting cells, and is an important growth factor for antigen primed Th2 cells [222] . IL-1 also potently induces the synthesis and release of multiple pro-inflammatory cytokines and chemokines. The IL-1 receptor antagonist (IL-1Ra) polypeptide shows significant homology with IL-1a and IL-1b and binds the IL-1 receptor. IL-1Ra has been isolated from multiple tissues including alveolar macrophages [223] , and inhibits most of the activities of IL-1 [224] . IL1-Ra blocks Th2 but not Th1 clonal proliferation in vitro and in the guinea pig reduces allergen induced BHR and pulmonary eosinophilia [225] . Manipulation of this endogenous control mechanism may therefore, impact on asthma and needs to be evaluated in the clinical setting.
Interleukin-10
Although IL-10 is a Th2-derived cytokine, it has antiinflammatory properties that could be used to control asthmatic inflammation. IL-10 is derived largely from mononuclear cells, alveolar macrophages and both naive and committed T-cells. It reduces MHC and costimulatory molecule expression, reduces pro-inflammatory cytokine release and increases IL-1Ra expression [4, 226] . T-cell and macrophage IL-10 synthesis is significantly reduced in asthmatic subjects compared with nonasthmatics [227, 228] but IL-10 expression in alveolar macrophages is increased by corticosteroid therapy [229] , suggesting in vivo relevance of this cytokine. A polymorphism in the promoter sequence of IL-10 has been associated with attenuated IL-10 expression and has been identified at increased frequency in severe asthma [230] , while promoter polymorphisms have been demonstrated in asthma probands and are associated with elevation of IgE levels [231] . This latter observation is of particular interest given a proposed suppressive effect of IL-10 on IL-4-induced IgE isotype switching by B-cells [232] . IL-10 administration to mice reduces airway eosinophilia and allergen-induced late responses [233] . When given to normal volunteers, IL-10 reduced circulating CD3, CD4 and CD8 lymphocyte numbers and the proliferative response and reduced TNF-a and IL-1 production [234] . Further studies in human asthma are awaited.
Use of antisense oligonucleotides
Oligonucleotide sequences forming a complementary copy of normal, or sense, messenger (mRNA) are able to bind to specific mRNA, and this dimer formation prevents mRNA translation and protein synthesis. The effectiveness of this technique was demonstrated in a rabbit model of asthma where aerosol inhalation of adenosine-A1 receptor antisense protected the animals from subsequent challenge with either adenosine or dust-mite allergen, with effects persisting up to 7 days [235, 236] . In a model in which the late allergic reaction could be transferred in the rat by ovalbumin sensitized T-cells [237] , IL-4 antisense-treated T-cells caused a significant reduction in the late allergic reaction, airway eosinophilia, and IL-4 and IL-5 expression. However, when IL-5 antisense treated T-cells were administered, only BAL IL-5 expression was reduced suggesting a key role for IL-4 in CD4+ T-cell mediated late allergic responses. In murine models, an IL-5 antisense oligonucleotide reduced IL-5 protein levels, airway eosinophilia and allergen-induced late allergic responses [111] . Similar approaches targetting CCR3 and the cytokine receptor a-subunits of IL-4, IL-13 and GM-CSF have also been reported with promising results [238± 240]. Antisense based therapies are currently in clinical use in the treatment of CMV retinitis and for advanced cancer [241±243] and are undergoing further safety and tolerability evaluation.
Use of gene therapy
The technique of gene therapy entails the specific augmentation of gene expression by transfer of single genes using viral vectors or liposome transfer [244±247]. Gene therapy has been explored in asthma models in mice where mucosal transfer of IL-12 [248] and IFN-c [249] significantly reduced Th2 cytokine expression and inhibited BHR. Transfer of the glucocorticoid receptor to the epithelial cell line A549, lead to repression of transcription factor mediated gene transcription and may provide a therapeutic approach in steroid-resistant asthma [250] . Gene transfer to the lungs in man is still in a developmental phase, and the efficiency of gene transfer using liposomal transfer technology is thus far suboptimal, as judged from the experience of the transfer of the cystic fibrosis transmembrane regulator DNA to patients with cystic fibrosis [251] . Use of the more efficient transfer system, the adenovirus vector, may be detrimental in inducing lung damage and inflammation, and is no longer a viable option in man. The potential genes that may be delivered to the airway epithelium of patients with asthma for therapeutic effects are numerous. Candidates for gene transfer might include Th1 cytokines IL-12 or IFN-c, or of the anti-inflammatory cytokine, IL-10, or of IL-1Ra, or of the corticosteroid receptor may be contemplated, but gene therapy approaches for the treatment of asthma remain in the distant future.
Conclusion
Recent advances in the techniques for the synthesis and manufacture of monoclonal antibodies, synthetic peptides and peptidomimetic small molecules has increased the potential for the creation of specific inhibitors of immune processes in allergic inflammation. These agents have enabled specific intervention in the inflammatory cascade and allow a clearer understanding of the roles of specific agents in this cascade, while at the same time providing the possibility of therapeutic intervention in asthma. In the first instance, it is likely that these strategies will be aimed at those with severe difficult-to-treat asthma as it is here that the failings of current therapies are most evident. Whether new therapies may provide remission of disease with shortterm treatment cannot be predicted from the current understanding of asthma. While preliminary data for many of these agents appears most promising, these agents will have to endure rigorous evaluation of efficacy, long-term safety and cost-effectiveness. Several agents targeted to specific immunological or cytokine pathways may become available and may be more effective in certain types of asthma. Genetic pharmacological profiling may be needed to identify the best responders to particular types of specific drugs [252] . The future of asthma therapy looks bright, but identifying targets is only a first step. The development of these new approaches is very exciting but the task remains daunting. 
